Raymond James raised the firm’s price target on Encompass Health (EHC) to $130 from $120 and keeps a Strong Buy rating on the shares. Encompass Health’s Q1 results were better than expected amid better than predicted discharge volume and labor expense, and also benefited from $3M of Medicaid supplemental payments, the analyst tells investors in a research note. The company also raised its medium term bed-addition guidance and planning to add 100-120 beds to existing facilities going forward, up from 100, to meet the ongoing strong demand, the firm says.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $130 from $110 at Mizuho
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating
- Encompass Health’s Strong Q1 2025 Performance and Strategic Moves Justify Buy Rating
- Encompass Health Stock (EHC) Surges Following Strong Q1 Results and Strategic Expansion Plans
- Encompass Health Reports Strong Q1 2025 Results